Aravind Eye Care ran cataract surgery as a production line, paying for free care

Cataracts are curable with a short operation, yet in the 1970s they were the leading cause of blindness across rural India — not because the surgery was hard, but because most of the country's cataract-blind population were poor farmers who could never pay a private surgeon's fee, and government and charity eye camps could only reach a fraction of them before running out of funding for the year. The standard response, then as now, was the same in every field with a poor-and-underserved population: raise more donations, run more free camps, ration the supply of care to the size of the grant.

Dr. Govindappa Venkataswamy, known as Dr. V, retired from government medical service in 1976 at 58 with arthritis so severe he could barely hold a scalpel standing up. He mortgaged his own house and pulled his siblings out of their medical practices to open an 11-bed clinic in Madurai, Tamil Nadu, with no endowment and no plan to depend on one — donor money that arrives in cycles cannot underwrite free surgery that needs to happen every day of the year.

Ran surgery as a production line: standardized steps, second table, mid-level staff for prep — paying patients' fees fund identical free surgeries.

Standardizing steps and adding a second table let surgeons operate continuously, multiplying daily surgeries fivefold.

Mid-level staff handled prep and sterilization, so surgeons only did the one step requiring their skill.

Identical clinical outcomes for paying and free patients made the fee pay for amenities, not better surgery.

Paying patients' fees directly covered the marginal cost of free surgeries, with no grant cycle delays.

When serving both paying and nonpaying customers, re-engineer delivery for volume so the paying tier's margin covers the free tier, instead of fundraising.

By the 2020s an Aravind ophthalmologist performed roughly 2,000 cataract surgeries a year against a national Indian average near 400, at a surgical cost of roughly $41–$125 versus $2,410–$5,243 in the United States, with complication rates about half those reported in the UK's National Health Service. Over half of all patients pay nothing or a steeply subsidized rate, funded entirely by the paying half, and the system has performed more than 6.8 million surgeries across over 55 million patient visits while remaining financially self-sustaining without ongoing donor subsidy.